We read with great interest the letter by Papaefthymiou *et al* \[[@ref1]\] concerning the Greek National Consensus on *Helicobacter pylori* *(H. pylori)* infection \[[@ref2]\]. We certainly agree with the authors that over the past years in order to overcome the fast-growing antibiotic resistance of *H. pylori* infection worldwide, an "add-on" strategy has been adapted, and that this is more obvious in countries like Greece, where bismuth salts are not commercially available. Thus, novel *H. pylori* eradication regimens, with a more targeted pathophysiological approach, are under evaluation and we are awaiting with great interest the results of the ongoing clinical trials.

Eradication of *H. pylori* infection has traditionally relied on empiric therapeutic regimens, since the need for endoscopy and the limited availability of culture, in most countries including Greece, have rendered the susceptibility-guided treatment option impractical or even unfeasible. Moreover, a recent randomized study showed that susceptibility-guided therapy in a high-resistance area was equally effective as a local empirical regimen \[[@ref3]\], while another randomized study failed to reveal superiority of genotypic resistance-guided therapy over a properly designed empirical treatment for eradication of refractory *H. pylori* infection \[[@ref4]\]. For these reasons, the Greek consensus has stated (Statement 26) that culture and antimicrobial susceptibility testing is not recommended before first-line therapy, and that susceptibility-guided therapy should be provided as a rescue treatment, especially after second-line treatment has failed.

On the other hand, the effect of vitamin D (vitD) on *H. pylori* infection and eradication rates has been widely investigated recently \[[@ref5]\]. VitD, apart from its well-known role in calcium and phosphorus metabolism, has been proven to be potent immune modulator of the adaptive immune system, stimulating the innate immune response upon infection \[[@ref6]\]. Based on these data, several clinical studies have illustrated that vitD analogs may have anti-*H. pylori* antimicrobial effects. Cytological research has also found that vitD~3~ decomposition product 1 can lyse *H. pylori* bacterial cells by inducing the collapse of the cell membrane \[[@ref7]\]. However, the correlation with vitD has not been fully clarified and studies of the impact of serum vitD levels on *H. pylori* eradication were mostly observational or retrospective and of small sample size \[[@ref8]-[@ref10]\]. Therefore, well-designed randomized controlled prospective studies with a large sample size are needed. We were delighted to hear that a national multicenter study on the relationship between vitD and *H. pylori* was recently launched and we are awaiting the results.
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